Genovis AB (publ.) (STO:GENO)

Market Cap	1.35B -13.3%
Revenue (ttm)	117.66M -10.3%
Net Income	21.18M -24.1%
EPS	0.32 -24.3%
Shares Out	66.06M
PE Ratio	63.35
Forward PE	48.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,622
Average Volume	49,861
Open	20.45
Previous Close	20.45
Day's Range	19.02 - 20.45
52-Week Range	17.10 - 29.90
Beta	2.12
RSI	41.56
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.